Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lambert-Eaton Myasthenic Syndrome 1Hodgkin Disease 1HIV Infections 1Burkitt Lymphoma 1Brain Neoplasms 1Autoimmune Diseases of the Nervous System 1Autoimmune Diseases 1

Interventions

thymoglobulin 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Etoposide 1Cytarabine 1Carmustine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Opsoclonus-Myoclonus Syndrome × carmustine, poliferprosan 20 drug combination × 1 year × Clear all
NCT00716066 2026-02-27

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
53 enrolled
CNS

Rasmussen subacute encephalitis, Autoimmune Diseases, Myasthenia Gravis, Neuromyelitis Optica, Lambert-Eaton Myasthenic Syndrome, Stiff-Person Syndrome, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Vasculitis, Central Nervous System, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡